Sustained API price weakness
API prices have declined 10-12% over the last 12 months and continue to slide, impacting CDMO revenue growth and margins.
AKUMS / bear-case history
Track the concerns that keep returning.
Akums Drugs and Pharmaceuticals · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Slow ramp-up in European exports
European dossier approvals and commercial supplies are still in early stages; achieving $100 million export target in 5 years may be delayed if regulatory or market access hurdles arise.
Trade generic and API losses persist
Trade generic segment posted negative EBITDA of ₹5 crore, and API business reported a loss of ₹6 crore. Management is rationalizing but turnaround timeline is uncertain.
GLP-1 opportunity not being pursued
Management confirmed they are not targeting semaglutide, citing limited CDMO addressable market as most players do it in-house. This could mean missing a large growth opportunity.